Holen Sie sich die Stockscreener-App
21.90
0.44%
-0.12
Schlusskurs vom Vortag:
$22.02
Offen:
$22.02
24-Stunden-Volumen:
320.66K
Relative Volume:
0.20
Marktkapitalisierung:
$3.74B
Einnahmen:
$1.07B
Nettoeinkommen (Verlust:
$391.00M
KGV:
9.57
EPS:
2.2884
Netto-Cashflow:
$6.31M
1W Leistung:
-2.82%
1M Leistung:
+6.38%
6M Leistung:
+0.85%
1J Leistung:
+46.26%
1-Tages-Spanne:
$21.77
$22.32
1-Wochen-Bereich:
$20.96
$22.66
52-Wochen-Spanne:
$14.08
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
21.92 | 3.75B | 1.07B | 391.00M | 6.31M | 2.2884 |
VRTX
Vertex Pharmaceuticals Inc
|
439.36 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.21 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
838.50 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
332.17 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.80 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-23 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
ACADIA Pharmaceuticals stock (US0042251084): Is the next product pipeline now the real test for sust - AD HOC NEWS
Acadia launches powder version of Rett syndrome treatment in the US - MSN
ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical - Yahoo
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Does ACADIA Pharmaceuticals Inc stock reflect fundamentals2026 Chart Watch & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Breakout Watch: What is the target price for ACADIA Pharmaceuticals Inc stockWeekly Profit Recap & Technical Pattern Based Signals - baoquankhu1.vn
ACADIA Pharmaceuticals Inc. (ACAD) stock price, news, quote and history - Yahoo Finance Singapore
ACADIA Pharmaceuticals Insider Sells Over $22,000 in Stock - National Today
ACAD Stock Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Neuren Pharmaceuticals advances Rett syndrome treatment with US launch of DAYBUE STIX - BioMelbourne Network
Sectors Review: Is ACADIA Pharmaceuticals Inc being accumulated by smart money2026 Biggest Moves & AI Driven Price Forecasts - baoquankhu1.vn
(ACAD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Acadia Pharma EVP Schneyer sells $60k in stock By Investing.com - Investing.com Australia
Acadia Pharmaceuticals officer sells $22,866 in stock By Investing.com - Investing.com Australia
Acadia Pharmaceuticals officer sells $22,866 in stock - Investing.com
Acadia Pharma EVP Schneyer sells $60k in stock - Investing.com
[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Acadia (NASDAQ: ACAD) officer sells shares to cover RSU tax obligations - Stock Titan
Acadia Pharmaceuticals Launches DAYBUE STIX for Rett Syndrome - National Today
Acadia Pharmaceuticals (ACAD) Expands Access to Rett Syndrome Tr - GuruFocus
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome - Bakersfield.com
User - The Chronicle-Journal
RBC Capital Adjusts ACADIA Pharmaceuticals PT to $29 From $30, Maintains Outperform Rating - Moomoo
ACADIA Pharmaceuticals Inc. (ACAD.MX) Income Statement - Yahoo! Finance Canada
Advantage Alpha Capital Partners LP's ACADIA Pharmaceuticals Inc(ACAD) Holding History - GuruFocus
IPO Launch: Is ACADIA Pharmaceuticals Inc being accumulated by smart money2026 Growth vs Value & Technical Confirmation Alerts - baoquankhu1.vn
ACADIA Pharmaceuticals Inc. $ACAD Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Trade Near Recent Levels - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
ACAD PE Ratio & Valuation, Is ACAD Overvalued - Intellectia AI
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Relay Therapeutics, Inc. Stock? - AAII
Insiders At ACADIA Pharmaceuticals Sold US$1.0m In Stock, Alluding To Potential Weakness - 富途牛牛
ACADIA Pharmaceuticals Inc (DR6.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Glioblastoma Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics, Autotelic Therapeuti - Barchart
BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating - MSN
Layoff Watch: Is ACADIA Pharmaceuticals Inc being accumulated by smart moneyStop Loss & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Update Recap: Can ACADIA Pharmaceuticals Inc continue delivering strong returns - baoquankhu1.vn
Acadia Pharmaceuticals stock drops 3.35% as company gears up for post-acute care conference - Traders Union
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Mixed Share Performance - simplywall.st
Acadia Pharma EVP Schneyer sells $159k in stock By Investing.com - Investing.com Australia
Acadia Pharma EVP Schneyer sells $159k in stock - Investing.com UK
Acadia Pharmaceuticals exec sells $41,895 in stock By Investing.com - Investing.com India
Acadia Pharmaceuticals exec sells $41,895 in stock - Investing.com
Acadia EVP Thompson sells $73k in stock after option exercise - Investing.com
Acadia EVP Rhodes sells $82k in stock after option exercise - Investing.com
Acadia Pharma CEO Owen Adams Catherine sells $249k in stock - Investing.com
Acadia Pharma CEO Owen Adams Catherine sells $249k in stock By Investing.com - Investing.com India
Acadia EVP Rhodes sells $82k in stock after option exercise By Investing.com - Investing.com South Africa
ACADIA (NASDAQ: ACAD) officer sells 1,942 shares after RSU vesting - Stock Titan
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):